$70 Million


Martin Shkreli is an American former hedge fund manager and convicted felon. He is also the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare. He is also the co-founder and former Chief Executive officer (CEO) of the mega pharmaceutical firm Retrophin and Turing Pharmaceuticals (now known as Vyera Pharmaceuticals); and the former CEO of start-up software company Gödel Systems, which was founded by him in August 2016. He is known for Turing Pharmaceuticals, Retrophin, and Daraprim price hikes. He has been convicted for securities fraud

and his penalty is seven years in prison along with $72 Million in fines. Shkreli is currently at the low-security federal prison in Allenwood, Pennsylvania and apparently, he is expected to get released in late 2023. In a recent judgment on January 14, 2022, Martin Shkreli has been banned from the pharmaceutical industry for life and has also been ordered to pay a $64.6 Million fine.

Martin Shkreli’s Net Worth

In January 2016, Fortune estimated that Shkreli’s net worth was at least $45 million but later updated its profile to reflect that the value of Shkreli’s E-Trade account had dropped by more than $40 million.” Shkreli leveraged a $4 million E-Trade account for his bail.

In June 2017, Reuters reported that Shkreli had reported his net worth at $70 million after being arrested in 2015 and that his attorney Benjamin Brafman, in a hearing before Judge Kiyo Matsumoto, had conceded that his client still owned shares of Turing Pharmaceuticals worth between $30 and $50 million.

Martin Shkreli Net Worth

Net Worth: $70 Million
Full Name: Martin Shkreli
Profession: Fund Manager
Monthly Income: $100 Thousand
Annual Income: $1-2 Million
Factors: MSMB Capital Management
Country: United States
Last Updated: 2022

Martin Shkreli Net Worth Growth

Net Worth in 2022 $70 Million
Net Worth in 2021 $70 Million
Net Worth in 2020 $70 Million
Net Worth in 2019 $70 Million
Net Worth in 2018 $70 Million
Net Worth in 2017 $70 Million

Early Life

Martin Shkreli was born in Coney Island hospital in the New york city borough of Brooklyn in the year 1983 on March 17, 1983, in New York City, United States. He is American by nationality. He was born to Albanian and Croatian immigrant parents.

His parents were Roman Catholic, and according to Martin Shkreli, his religion has been “a guiding post” for him, although he is supposedly an atheist. His parents immigrated to the United States and worked as janitors there. He, his two sisters, and his brother grew up in a working-class community in sheepshead bay, Brooklyn. By most accounts, Shkreli was raised Catholic and also attended Sunday school as a child.

As far as schooling is concerned  Shkreli attended Hunter College High School. Though it is still debated as to whether Shkreli graduated from Hunter or whether he was expelled before his senior year and actually received the credits necessary for his high school diploma through City-as-school high school.  He ended up being a part of a program that placed him in an internship at Wall Street hedge fund Cramer, Berkowitz, and Company when he was only 17. Shkreli received a Bachelor’s degree in Business Communication from Baruch College in 2004.

According to Vanity Van, Shkreli told them that he developed an interest in chemistry when a family member suffered from treatment-resistant depression.


Martin Shkreli then went ahead to work with Cramer Berkowitz and the company.

During Shkreli’s time at Cramer, Berkowitz, and Company, he advised short-selling the stock of Regeneron Pharmaceuticals, a biotech company testing a weight-loss drug. When its price dropped in accordance with Shkreli’s prediction, Cramer’s hedge fund profited. Shkreli’s prediction drew the attention of the Securities and Exchange Commission, which investigated Shkreli’s knowledge about the stock but was not able to prove wrongdoing on his part.

After four years as an associate at Cramer Berkowitz, Shkreli worked as a financial analyst for Intrepid Capital Management and UBS Wealth Management. He then started his first hedge fund, Elea Capital Management, in the year 2006.

 In September 2009, Shkreli started MSMB Capital Management, which took its name from the initials of the two founding portfolio managers, Shkreli and his childhood friend, Marek Biestek. Shkreli and Biestek used to shortlist biotech companies, then described flaws in the companies on stock trading chat rooms.

Shkreli founded Retrophin in 2011 under the MSMB umbrella and ran it as a portfolio company with an emphasis on biotechnology, to create treatments for rare diseases.

Retrophin’s board decided to replace Shkreli in September 2014, and he resigned from the company the following month. He was replaced by Stephen Aselage.

After Shkreli’s departure, Retrophin filed a US$65 million lawsuit against him in August 2015, claiming that he had breached his duty of loyalty to the biopharmaceutical company in a long-running dispute over his use of company funds

Shkreli founded Turing Pharmaceuticals in February 2015, after his departure from Retrophin. He launched Turing with three drugs in development acquired from Retrophin: An intranasal version of ketamine for depression, an intranasal version of oxytocin, and Vecamyl for hypertension. On August 10, 2015, Turing acquired Daraprim, a medication approved by the FDA in 1953 from Impax Laboratories for the US $55 million. He was then involved in the Daraprim price- hike controversy.

After Shkreli was imprisoned, Turing changed its name to Vyera in 2017 to avoid negative publicity and is presently named Phoenixus. In March 2019, The Wall Street Journal reported that Shkreli “steers his old company from prison.”

Martin Shkreli Net Worth And Salary
Martin Shkreli Net Worth And Salary


Shkreli drew notoriety in 2015 after hiking Daraprim’s price overnight to $750 per tablet from $17.50. The drug treats toxoplasmosis, a parasitic infection that threatens people with weakened immune systems. Shkreli was sued in January 2020 for allegedly violating anti-trust rules over fixing the price over the anti-parasitic drug Daraprim and “delaying the entry of generic competition for at least 18 months” according to the ruling.

He was also accused of creating two companies, Vyera and Retrophin (NASDAQ: TVTX) Inc, designed to monopolize drugs so he could profit “on the backs” of patients, doctors, and distributors.

Shkreli is serving a seven-year prison sentence for securities fraud.

Vyera was founded in 2014 as Turing Pharmaceuticals and acquired Daraprim from Impax Laboratories Inc in 2015.

Regulators accused Vyera of protecting its dominance of Daraprim by ensuring that generic drugmakers could not obtain samples for cheaper versions and keeping potential rivals from buying a key ingredient.

In a recent judgment on 14 January 2022 Martin Shkreli has been banned from the harmaceutical industry for life and he has also been ordered to pay $64.6 Million as a fine.

US District Judge Denise Cote said in a 135-page ruling that “Shkreli’s egregious, deliberate, repetitive, long-running and ultimately dangerous illegal conduct warranted the stiff penalty.”

She said that the Daraprim scheme was also alleged to be “particularly heartless and coercive”

“Shkreli’s anti-competitive conduct at the expense of the public health was flagrant and reckless,” the judge wrote barring him from the opportunity to repeat that conduct is nothing if not in the interest of justice.” and a lifetime industry ban was needed because of the “real danger” that Shkreli could become a repeat offender.

Favorite Things

Favorite Actor Robert Downey Jr.
Favorite Actress Not Know
Favorite Singer Not Know
Favorite App YouTube
Favorite Game N/A
Favorite Food Not Know
Favorite Song Not Know
Favorite Sportsman Lionel Andrés Messi
Favorite Movie Don’t Know
Favorite Cricketer Virat Kohli
Favorite Footballer Lionel Andrés Messi
Favorite TV Show Not Know
Hobbies Driving


Net Worth $70 Million
Name Martin Shkreli
Age 38
Height (1.8 m)
Weight 80KG (Approx)
Profession Fund Manager
Date Of Birth March 17, 1983
Birthplace United States
Nationality American
Income $2 Million (Annual)
Spouse N/A

Personal Life

In December 2020, it was reported that Shkreli was in a relationship with Christie Smythe, a former reporter for Bloomberg News who also broke the news of Shkreli’s arrest in 2015. Smythe described their relationship as being “life partners”. In October 2021, Smythe said the two had broken up but are still friends. He is also an avid League of Legends Player. 

In February 2017, Shkreli was invited to speak at Harvard University. The requested travel was approved by a judge.

As of 2022, Martin Shkreli‘s net worth is estimated at roughly $70 million.

Source link


Please enter your comment!
Please enter your name here